Carlyle price target lowered to $47 from $50 at BofA
BofA analyst Craig Siegenthaler lowered the firm’s price target on Carlyle (CG) to $47 from $50 and keeps an Underperform ...
The Search For 7% Investment Grade Yields, Part 2: Carlyle And Its Baby Bond
The Carlyle Group offers solid investment-grade debt with consistent dividends. Learn why CG stock’s baby bond, CGABL, is a ...
BioPharma Dive19h
Bluebird, at risk of default, agrees to take-private deal
The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...
Carlyle's profit misses estimates as private equity business weighs
Carlyle Group's distributable fourth-quarter earnings missed market expectations on Tuesday, eclipsing a strong growth in the ...
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.
Carlyle Group Enters Indian Auto Parts Industry With Highway-Roop Platform Buy
(Reuters) - U.S.-based investment firm Carlyle Group has entered India's auto components market by buying a controlling stake ...
FiercePharma20h
Once valued at $10B, bluebird bio sold to private equity firms for $29M
There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...
Carlyle's Savino Expects IPOs to Increase in 2025
Matt Savino, Carlyle global head of capital markets, expects the IPO market to improve in 2025. He is on "Bloomberg ." ...